CRISPR for Cancer: How Gene Editing Is Revolutionizing Cancer Treatment in 2026

The Convergence of Gene Editing and Cancer Treatment

Cancer has always been, at its core, a disease of the genome. Mutations accumulate, tumor suppressors fail, oncogenes activate, and cells begin to divide without restraint. For decades, oncology fought this genomic disease with blunt instruments -- chemotherapy that poisons dividing cells indiscriminately, radiation that burns tissue in a targeted radius, surgery that cuts away visible masses. These approaches saved millions of lives, but they were never precise enough to match the molecular complexity of the disease they were fighting.

CRISPR changed the equation. When Emmanuelle Charpentier and Jennifer Doudna published their landmark 2012 paper describing a programmable system for cutting DNA at precise locations, cancer researchers immediately recognized the implications. If cancer is a disease of broken genes, then a tool that can rewrite genes with surgical precision is, conceptually, the ideal weapon against it.

By 2026, that conceptual promise has translated into clinical reality. More than 30 CRISPR-focused cancer trials are active or recruiting worldwide. Several gene-edited cell therapies have produced remission rates that would have seemed improbable a decade ago. The field has moved well beyond proof-of-concept into a phase of rapid clinical expansion, with programs targeting blood cancers, solid tumors, and the immune system's own limitations.

This article provides a comprehensive overview of where CRISPR-based cancer treatment stands today: what has worked, what is coming next, and what challenges remain.

How CRISPR Improves CAR-T Cell Therapy

CAR-T cell therapy -- in which a patient's T cells are extracted, engineered to express a chimeric antigen receptor that targets cancer, and infused back into the body -- was already one of the most important advances in cancer treatment before CRISPR entered the picture. Products like Kymriah and Yescarta demonstrated that engineered immune cells could achieve durable remissions in patients who had exhausted all other options.

But conventional CAR-T therapy has significant limitations. Manufacturing takes weeks because each dose must be custom-built from the patient's own cells. Some patients' T cells are too damaged by prior chemotherapy to produce an effective product. The cost exceeds $400,000 per infusion. And even when the treatment works initially, tumors often develop escape mechanisms -- they downregulate target antigens, they exploit immune checkpoints like PD-1 to shut down the attacking T cells, or they create immunosuppressive microenvironments that neutralize the engineered cells.

CRISPR addresses these limitations on multiple fronts.

PD-1 Knockout: Removing the Immune Brake

One of the most studied CRISPR modifications in cancer immunotherapy is the knockout of the PD-1 gene (PDCD1) in T cells. PD-1 is an immune checkpoint receptor -- a molecular "off switch" that cancer cells exploit to disable T cells. Tumors frequently express PD-L1, the ligand for PD-1, effectively telling approaching T cells to stand down.

Checkpoint inhibitor drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) work by blocking this interaction with antibodies. They have transformed treatment for melanoma, lung cancer, and other solid tumors. But antibody-based checkpoint blockade is systemic -- it affects the entire immune system, leading to autoimmune side effects in a significant fraction of patients.

CRISPR offers a more targeted approach: instead of blocking PD-1 across the whole body with an antibody, you can delete the PD-1 gene directly from the therapeutic T cells before infusing them. This makes the engineered cells permanently resistant to PD-L1-mediated suppression without affecting the rest of the immune system.

The clinical results from this approach have been striking. Trials conducted in China using CRISPR-edited, PD-1 knockout T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) have reported an overall response rate (ORR) of 100 percent, with a complete response (CR) rate of 87.5 percent. These numbers emerge from a patient population that had failed multiple prior lines of therapy, including conventional CAR-T in some cases. The removal of PD-1 appears to give the engineered T cells a decisive advantage in overcoming tumor-mediated immune suppression, particularly in patients whose cancers had developed resistance to earlier immunotherapies.

These results must be interpreted with appropriate caution -- the cohorts are relatively small, and long-term follow-up is ongoing. But the signal is strong enough that PD-1 knockout has become one of the most common CRISPR modifications in the cancer immunotherapy pipeline.

Allogeneic (Off-the-Shelf) CAR-T: Why It Matters

Perhaps the most transformative application of CRISPR in CAR-T therapy is the creation of allogeneic, or "off-the-shelf," products. In conventional autologous CAR-T, each patient's cells must be individually collected, shipped to a manufacturing facility, engineered, expanded, quality-tested, and shipped back. This process takes three to five weeks -- an eternity for patients with aggressive cancers that may progress during the wait. It also means that patients with compromised immune systems or insufficient T cell counts may not be eligible at all.

Allogeneic CAR-T takes a fundamentally different approach: T cells are collected from healthy donors and edited using CRISPR to remove genes that would cause two critical problems:

Graft-versus-host disease (GvHD): Donor T cells would normally attack the recipient's tissues. CRISPR knockout of the T-cell receptor (TCR) genes -- specifically TRAC (T-cell receptor alpha constant) -- eliminates this risk by preventing the donor cells from recognizing the recipient's tissues as foreign.
Host-versus-graft rejection: The recipient's immune system would normally destroy the foreign donor cells. CRISPR knockout of beta-2-microglobulin (B2M), which is required for MHC class I expression on the cell surface, makes the donor cells invisible to the recipient's CD8+ T cells.

With these edits in place, a single manufacturing run from one healthy donor can produce hundreds or thousands of doses. The cells can be frozen, stored, and administered to any patient within days of diagnosis -- no waiting, no personalized manufacturing, no dependency on the patient's own immune health.

The economic implications are enormous. If allogeneic CAR-T can match the efficacy of autologous products, it could reduce costs by an order of magnitude and make the therapy accessible in settings where autologous manufacturing infrastructure does not exist.

CRISPR Therapeutics: Zugo-cel (CTX112) Sets a New Standard

CRISPR Therapeutics, co-founded by Emmanuelle Charpentier, has emerged as one of the front-runners in allogeneic CAR-T development. The company's lead oncology program, CTX112 (zugo-cel), targets CD19 -- the same antigen pursued by Kymriah and Yescarta -- but does so using an off-the-shelf, CRISPR-edited allogeneic product.

CTX112 incorporates multiple CRISPR-mediated edits: TCR knockout to prevent GvHD, B2M knockout to reduce rejection, and targeted insertion of the CD19-directed CAR construct into the TRAC locus. This last feature is particularly elegant -- by inserting the CAR gene directly into the disrupted TCR gene, CRISPR Therapeutics achieves two objectives with a single edit: the TCR is disabled, and the CAR is expressed under the control of the TCR's endogenous promoter, which may provide more physiological regulation of CAR expression than the viral promoters used in conventional approaches.

The clinical results have been exceptional. In trials enrolling patients with relapsed or refractory large B-cell lymphoma (LBCL), CTX112 has achieved an overall response rate of approximately 90 percent and a complete response rate of 70 percent. These figures are notable not only for their magnitude but for the context: they are being achieved with an off-the-shelf product that does not require patient-specific manufacturing.

CRISPR Therapeutics has indicated that it plans to expand CTX112 development beyond oncology into autoimmune diseases -- a logical extension given that CD19-targeted therapies have shown surprising efficacy in depleting the autoreactive B cells that drive conditions like lupus and multiple sclerosis. If the same off-the-shelf product can treat both cancer and autoimmune disease, the commercial and clinical implications are vast.

The company also has earlier-stage programs, including CTX131 targeting CD70 for renal cell carcinoma and CTX130 targeting CD70 for T-cell lymphomas, further broadening its CRISPR-edited allogeneic pipeline.

BE-CAR7: Base Editing Achieves 82 Percent Remission in T-ALL

One of the most celebrated results in the CRISPR cancer treatment landscape comes not from conventional CRISPR-Cas9 cutting but from base editing -- a more precise variant developed by David Liu at the Broad Institute that can change individual DNA letters without creating double-strand breaks.

The program is BE-CAR7, developed at Great Ormond Street Hospital (GOSH) in London, and it targets T-cell acute lymphoblastic leukemia (T-ALL), a particularly challenging cancer to treat with conventional CAR-T. The difficulty is that T-ALL is a cancer of T cells themselves, meaning that both the cancer cells and the therapeutic CAR-T cells share the same surface markers. A conventional CD7-directed CAR-T cell would attack not only the leukemia but also itself and other healthy T cells -- a problem called fratricide.

Base editing solved this by making four simultaneous edits to healthy donor T cells:

CD7 knockout: The CD7 gene is disabled in the donor T cells so that the anti-CD7 CAR does not trigger self-destruction.
CD52 knockout: CD52 is removed so the edited cells survive alemtuzumab, a CD52-targeting antibody used for lymphodepletion.
TCR knockout: The T-cell receptor is disabled to prevent graft-versus-host disease.
CAR insertion: The anti-CD7 chimeric antigen receptor is added, directing the cells to kill CD7-expressing leukemia cells.

The precision of base editing -- which changes single nucleotides rather than cutting the DNA backbone -- reduces the risk of unintended chromosomal rearrangements that can occur when multiple CRISPR-Cas9 cuts are made simultaneously. This matters because making four edits at once with conventional Cas9 carries a meaningful risk of translocations between the four cut sites.

The results, published in the New England Journal of Medicine, showed that BE-CAR7 achieved remission in approximately 82 percent of children with relapsed T-ALL who had no other treatment options. This is a patient population with an otherwise dismal prognosis -- children who had relapsed after chemotherapy, and often after one or more failed attempts at stem cell transplant.

The GOSH team, led by Professor Waseem Qasim, has described the approach as a proof-of-concept for multiplexed base editing in cell therapy. The success of BE-CAR7 has catalyzed interest in base editing as a manufacturing platform for complex multi-edited cell products, not just in cancer but across gene therapy more broadly.

Caribou Biosciences: CB-010 and CB-011

Caribou Biosciences, co-founded by Jennifer Doudna, has taken a differentiated approach to allogeneic CAR-T using its proprietary chRDNA (CRISPR hybrid RNA-DNA) technology, which the company says improves editing specificity by reducing off-target effects compared to standard guide RNAs.

CB-010: PD-1 Knockout Anti-CD19 CAR-T

CB-010 is Caribou's lead program, targeting CD19-positive B-cell malignancies. What distinguishes CB-010 from other allogeneic CD19 CAR-T products is its specific use of PD-1 knockout (via disruption of the PDCD1 gene) as a key component of the editing strategy. While all allogeneic programs include TCR knockout and some form of immune evasion editing, CB-010 adds the PD-1 knockout to give the cells an intrinsic checkpoint resistance advantage.

Early clinical data from the ANTLER trial showed encouraging results in patients with relapsed or refractory large B-cell lymphoma, with complete response rates that compare favorably to autologous CAR-T benchmarks. Caribou has emphasized that the PD-1 knockout component appears to contribute meaningfully to the durability of responses -- a critical factor given that many allogeneic CAR-T products have struggled with persistence.

CB-011: Targeting BCMA for Multiple Myeloma

CB-011 targets BCMA (B-cell maturation antigen), extending Caribou's allogeneic platform to multiple myeloma. This program is particularly notable because it incorporates an engineered surface protein designed to protect the edited cells from the recipient's NK (natural killer) cells -- a rejection pathway that B2M knockout alone does not fully address. By adding a non-cleavable HLA-E construct, CB-011 presents a "don't kill me" signal to NK cells, potentially improving the persistence and efficacy of the allogeneic product in patients with intact innate immunity.

Clinical data from the CaMMouflage trial are still maturing, but the approach represents an important evolution in the allogeneic CAR-T field: rather than simply removing signals that trigger rejection, the next generation of products is actively engineering in signals that promote acceptance and survival.

The Allogeneic vs. Autologous Debate: Why Off-the-Shelf Matters

The choice between autologous (patient-derived) and allogeneic (donor-derived) CAR-T is one of the defining questions in cell therapy today. The trade-offs are real on both sides.

Autologous advantages: The patient's own cells do not trigger immune rejection, allowing them to persist for months or years. This long-term persistence is thought to be important for durable remissions and for surveillance against relapse. The approved autologous products (Kymriah, Yescarta, Breyanzi, Abecma, Carvykti) have demonstrated this durability in large patient cohorts with years of follow-up data.

Autologous limitations: Manufacturing takes weeks. Cost exceeds $400,000 per dose. Patients with compromised T cells may fail to produce an adequate product. Some patients die or deteriorate during the manufacturing delay. The logistics of personalized manufacturing limit access to major academic medical centers in wealthy countries.

Allogeneic advantages: Immediate availability. A single manufacturing run produces hundreds of doses. Costs could drop below $50,000 per dose at scale. Any patient can receive treatment regardless of their own T cell health. Treatment can begin within days of diagnosis.

Allogeneic limitations: Donor cells are recognized as foreign and eventually rejected by the host immune system, limiting persistence. Most allogeneic programs report that the edited cells persist for weeks to a few months -- a much shorter duration than autologous products. This may explain why some allogeneic trials show high initial response rates but higher relapse rates. Repeated dosing is possible but adds complexity.

The field is actively working to close the persistence gap. Strategies include more sophisticated immune evasion editing (like Caribou's HLA-E approach), combining allogeneic CAR-T with short courses of immunosuppression, and developing "stealth" cells that can evade both adaptive and innate immune rejection.

If allogeneic products can demonstrate durability comparable to autologous therapies, they will likely become the default approach for most patients. The cost and access advantages are simply too large to ignore.

PD-1 Knockout T Cells: The China Trials

China has been at the forefront of CRISPR-based cancer immunotherapy since 2016, when Sichuan University conducted the world's first human CRISPR trial -- injecting PD-1-knocked-out T cells into a patient with metastatic non-small cell lung cancer. Since then, Chinese researchers have accumulated the largest clinical dataset on PD-1-edited immune cells in cancer.

The most compelling results come from trials using CRISPR-edited, PD-1-knockout T cells in B-cell non-Hodgkin lymphoma. Published data report an overall response rate of 100 percent and a complete response rate of 87.5 percent -- numbers that exceed what has been achieved with conventional CAR-T alone in comparable patient populations.

The approach is straightforward in concept: T cells are collected from the patient, the PDCD1 gene is disrupted using CRISPR-Cas9, a CAR construct targeting CD19 is inserted, and the cells are expanded and infused back. The PD-1 knockout ensures that the tumor cannot use the PD-1/PD-L1 checkpoint to disable the attacking cells.

What makes these results particularly notable is the patient population. These are individuals with multiply relapsed or refractory B-NHL -- patients who have failed multiple prior lines of therapy, often including rituximab, various chemotherapy regimens, and in some cases prior CAR-T. The fact that PD-1-edited CAR-T can achieve 100 percent ORR in this population suggests that checkpoint resistance may be a critical factor in overcoming treatment-resistant disease.

Several research groups across China have published results from related trials with various CRISPR-edited T cell products. While the regulatory environment and reporting standards differ from the U.S. and Europe, the consistency of the results across multiple centers adds weight to the findings. The data have contributed to growing international interest in incorporating PD-1 editing as a standard feature of next-generation CAR-T products.

In Vivo CAR-T: The UCSF Breakthrough

All of the approaches discussed so far share a common feature: T cells are edited outside the body (ex vivo), then infused back into the patient. This requires cell collection, manufacturing facilities, and a multi-step production process. The logical next question is whether the same editing can be done directly inside the patient's body.

In 2025, researchers at the University of California, San Francisco (UCSF) demonstrated that this is possible. Using lipid nanoparticles (LNPs) -- the same delivery technology that powers mRNA COVID-19 vaccines -- the team delivered CRISPR components and CAR-encoding mRNA directly into T cells circulating in the bloodstream of living mice. The result: functional CAR-T cells were generated in vivo, without any cell collection, ex vivo manipulation, or reinfusion.

This is a conceptual leap. If in vivo CAR-T can be translated to humans, it would eliminate the entire manufacturing infrastructure that currently makes CAR-T therapy expensive and inaccessible. A patient could receive an injection or infusion and their own T cells would be reprogrammed in place to become cancer fighters.

The UCSF approach used LNPs decorated with antibodies that target T cells specifically, ensuring that the mRNA cargo is delivered to the right cell type. Once inside the T cell, the mRNA is translated into the CAR protein and the CRISPR components that make the necessary genomic edits. The T cell is reprogrammed without ever leaving the body.

There are significant challenges to overcome before this reaches the clinic. The efficiency of in vivo editing is lower than ex vivo editing. The durability of in vivo-generated CAR-T cells is unknown. Safety concerns around off-target delivery -- LNPs reaching the wrong cell types -- must be thoroughly addressed. And the regulatory pathway for an injectable gene-editing therapy that modifies immune cells in vivo is uncharted territory.

Nevertheless, the UCSF work represents a credible path toward what many in the field consider the ultimate goal: a simple, injectable cancer treatment that reprograms the immune system using gene editing, available to any patient anywhere, at a fraction of current costs. Several biotech companies, including Capstan Therapeutics (which later merged into a broader effort) and others, are pursuing similar approaches.

CRISPR for Solid Tumors: The Hardest Problem in Cancer Immunotherapy

Blood cancers -- leukemias, lymphomas, and myeloma -- have been the proving ground for both conventional and CRISPR-edited CAR-T therapy. Solid tumors, which account for roughly 90 percent of cancer deaths, remain a vastly more difficult challenge.

The reasons are multiple and compounding:

Antigen heterogeneity: Solid tumors express target antigens inconsistently. Unlike B-cell cancers, where virtually every malignant cell expresses CD19, a solid tumor mass may contain subpopulations that express, underexpress, or entirely lack any given surface marker. A CAR-T product targeting a single antigen may kill some tumor cells while leaving others untouched, enabling resistant clones to repopulate.

Physical barriers: Solid tumors are surrounded by dense stromal tissue, dysfunctional blood vessels, and fibrotic extracellular matrix that physically prevent T cells from infiltrating the tumor mass. Even if CAR-T cells reach the periphery of a solid tumor, they may be unable to penetrate deep enough to reach all cancer cells.

Immunosuppressive microenvironment: Solid tumors create a hostile local environment that actively disables immune cells. They recruit regulatory T cells and myeloid-derived suppressor cells, secrete immunosuppressive cytokines like TGF-beta and IL-10, deplete nutrients that T cells need to function, and express multiple immune checkpoint ligands beyond PD-L1.

Lack of universal targets: There is no "CD19 of solid tumors" -- no single surface antigen that is uniformly expressed on cancer cells and absent from essential healthy tissues.

CRISPR is being applied to address several of these barriers simultaneously.

The NRF2 CRISPR Strategy

One of the more creative CRISPR approaches to solid tumors targets NRF2 (nuclear factor erythroid 2-related factor 2), a transcription factor that many solid tumors hijack to protect themselves from oxidative stress and chemotherapy. NRF2 activation is particularly common in lung cancer, where it drives resistance to cisplatin and other standard-of-care drugs.

Researchers have used CRISPR to knock out NRF2 in cancer cell lines and animal models, demonstrating that NRF2 disruption sensitizes tumors to chemotherapy and reduces their ability to resist oxidative damage from immune cells. The strategy is not to edit the immune cells but rather to use CRISPR to disable one of the tumor's key defense mechanisms.

Translating this to clinical application will require in vivo delivery of CRISPR directly to tumor cells -- a delivery challenge that remains unsolved at scale. But the NRF2 approach illustrates an important principle: CRISPR can target the cancer itself, not just the immune response to cancer.

Multi-Antigen and Logic-Gated CARs

CRISPR is enabling the construction of increasingly sophisticated CAR designs for solid tumors. Using multiplexed editing, researchers can insert multiple CAR constructs into T cells, each targeting a different tumor antigen. Combined with synthetic biology circuits -- AND gates that require two antigens to be present before the T cell activates, NOT gates that prevent activation when a healthy tissue marker is detected -- CRISPR-edited T cells can be programmed to discriminate between tumor and healthy tissue with much greater precision than single-antigen CARs.

These "armored" CAR-T cells can also be edited to express cytokines that remodel the tumor microenvironment, secrete enzymes that degrade the tumor's physical barriers, or resist the immunosuppressive signals that solid tumors deploy. Each of these features requires additional genetic modifications -- precisely the kind of multiplexed editing at which CRISPR excels.

Cancer Immunotherapy and CRISPR: The Broader Convergence

The integration of CRISPR into cancer immunotherapy extends well beyond CAR-T. Gene editing is being applied across the immunotherapy landscape in ways that are reshaping the field's trajectory.

CRISPR Screens for Target Discovery

CRISPR loss-of-function screens have become one of the most powerful tools for identifying new cancer vulnerabilities. In these experiments, researchers create libraries of tens of thousands of guide RNAs, each targeting a different gene, and introduce them into cancer cells or immune cells. By tracking which gene knockouts kill cancer cells, enhance immune recognition, or overcome drug resistance, scientists can systematically map the genetic dependencies of specific cancer types.

These screens have identified entirely new therapeutic targets that would not have been discovered through traditional approaches. They have also revealed unexpected genetic interactions that explain why some tumors resist treatment and have suggested combination strategies that are now entering clinical trials.

Editing Tumor-Infiltrating Lymphocytes (TILs)

Tumor-infiltrating lymphocytes -- immune cells that have naturally migrated into a tumor -- are already recognized as a promising therapeutic modality. TIL therapy involves extracting these cells from a patient's tumor biopsy, expanding them in the laboratory, and infusing them back at much higher numbers. The FDA approved the first TIL therapy, lifileucel (Amtagvi), in 2024 for melanoma.

CRISPR is now being used to enhance TILs before reinfusion. By knocking out exhaustion markers, immune checkpoints, or genes that limit T cell fitness, researchers aim to create "super TILs" that are more potent and persistent than their unedited counterparts. This approach has the advantage of working with T cells that already recognize the patient's specific tumor antigens -- a natural targeting mechanism that does not require engineering a CAR construct.

Engineering Macrophages and NK Cells

T cells are not the only immune cells being edited. CRISPR is being applied to natural killer (NK) cells and macrophages to create new classes of cell therapy products.

NK cell therapies offer several advantages: NK cells have natural anti-tumor activity, they do not cause graft-versus-host disease even when derived from donors, and they can be sourced from cord blood or iPSC-derived lines for scalable manufacturing. CRISPR editing of NK cells -- to add CARs, remove checkpoint receptors, or enhance persistence -- is in early clinical development.

CRISPR-edited macrophages (CAR-M) represent a particularly intriguing approach for solid tumors. Macrophages are inherently better at infiltrating solid tissues than T cells and can physically engulf tumor cells. By engineering macrophages to express CARs directed at tumor antigens, researchers are creating a cell therapy modality specifically designed to address the solid tumor infiltration challenge.

The Clinical Trial Landscape: 30+ CRISPR Cancer Trials and Growing

As of early 2026, more than 30 clinical trials involving CRISPR-based approaches to cancer treatment are active, recruiting, or recently completed. These trials span multiple continents, cancer types, and gene-editing strategies.

Blood cancers remain the largest category, with allogeneic CAR-T trials from CRISPR Therapeutics, Caribou Biosciences, Allogene Therapeutics, and others targeting CD19-positive B-cell malignancies, BCMA-positive multiple myeloma, and CD70-positive T-cell lymphomas.

Solid tumors are represented by a growing number of trials, including CRISPR-edited TIL therapies, PD-1-knockout T cell therapies for non-small cell lung cancer and esophageal cancer, and early-phase studies of CRISPR-based strategies to modify the tumor microenvironment.

Gene editing targets in these trials include:

TRAC (T-cell receptor alpha chain): Knocked out in virtually all allogeneic products to prevent GvHD.
B2M (beta-2 microglobulin): Knocked out to reduce immune rejection of allogeneic cells.
PDCD1 (PD-1): Knocked out to provide checkpoint resistance.
CD52: Knocked out to allow selective lymphodepletion with alemtuzumab while sparing the edited cells.
CD7: Knocked out in anti-CD7 CAR-T products to prevent fratricide when treating T-cell cancers.
CISH: Knocked out in some TIL programs, as CISH is a negative regulator of T cell receptor signaling.
TGF-beta receptor: Knocked out to protect T cells from the immunosuppressive TGF-beta signaling in the tumor microenvironment.

The trial landscape reflects a broader shift in oncology drug development. Gene-edited cell therapies are no longer experimental curiosities confined to a handful of academic centers. They are being advanced through registrational trials by well-funded companies with manufacturing capacity and regulatory strategies designed to support commercial approval.

The Next Frontier: Personalized Neoantigen Targeting

Perhaps the most ambitious application of CRISPR in cancer treatment is personalized neoantigen targeting. Neoantigens are mutant proteins found on the surface of cancer cells that are unique to each patient's tumor. Because they arise from somatic mutations, they are not present on any healthy cells, making them ideal targets for immune therapy -- if you can identify them and engineer an immune response against them.

The workflow is computationally and biologically complex:

Sequence the patient's tumor to identify somatic mutations.
Predict which mutations produce neoantigens that will be presented on the tumor's MHC molecules and recognized by T cells.
Use CRISPR to engineer T cells with TCRs or CARs that specifically recognize the patient's unique neoantigens.
Manufacture, expand, and infuse the personalized product.

This approach combines the precision of personalized genomics with the power of CRISPR engineering. Early-phase clinical trials, including work by PACT Pharma (now part of broader collaborations) and academic groups, have demonstrated that it is technically feasible to identify patient-specific neoantigens and engineer T cells against them. The challenge is speed and cost -- the entire process currently takes months and costs hundreds of thousands of dollars per patient.

CRISPR is particularly well-suited to this application because it enables rapid, precise insertion of new TCR sequences into T cells. As the turnaround time for sequencing, neoantigen prediction (increasingly aided by AI and machine learning), and cell manufacturing continues to decrease, personalized neoantigen-directed CRISPR therapy may become a practical clinical option for patients with solid tumors that lack universal surface targets.

In Vivo Gene Editing: The Future Beyond Cell Therapy

The long-term trajectory of CRISPR in cancer treatment points toward in vivo editing -- modifying genes directly inside the patient's body without any cell extraction or ex vivo manufacturing. The UCSF in vivo CAR-T work described earlier is one manifestation of this vision, but the concept extends further.

Imagine a future in which a cancer patient receives an intravenous infusion of lipid nanoparticles carrying CRISPR components programmed to:

Edit circulating T cells to express a CAR targeting the patient's tumor.
Knock out PD-1 in those same T cells.
Simultaneously deliver a second nanoparticle payload to the tumor itself, knocking out NRF2 or another resistance gene.

This kind of combinatorial in vivo editing is technically beyond current capabilities, but each individual component -- in vivo T cell editing, in vivo tumor gene disruption, LNP-mediated delivery -- has been demonstrated in preclinical models. The engineering challenge is integration, optimization, and safety validation.

The regulatory implications of in vivo gene editing for cancer are profound. Unlike ex vivo cell therapy, where the edited cells can be characterized and tested before infusion, in vivo editing modifies cells inside the patient's body with no opportunity for quality control before the edits take effect. Regulators will need to develop entirely new frameworks for assessing the safety and efficacy of these approaches.

Challenges and Open Questions

For all its promise, CRISPR-based cancer treatment faces substantial challenges that should temper premature enthusiasm.

Off-target editing: CRISPR can cut DNA at unintended sites in the genome, potentially disrupting tumor suppressor genes or activating oncogenes. While newer variants of Cas9 and alternative approaches like base editing and prime editing have significantly reduced off-target rates, the risk is not zero. For a cancer therapy -- where the goal is to fix genomic damage, not create new damage -- this concern is particularly acute.

Chromosomal rearrangements: When multiple CRISPR cuts are made simultaneously (as in allogeneic CAR-T manufacturing, where three or more genes are edited at once), the free DNA ends can rejoin incorrectly, creating translocations. This is a known risk of multiplexed Cas9 editing and is one of the motivations for adopting base editing (as in BE-CAR7), which does not create double-strand breaks.

Immune responses to Cas9: The Cas9 protein is derived from bacteria (Streptococcus pyogenes is the most common source), and a significant fraction of the human population has pre-existing immunity to it. If Cas9 protein persists in edited cells, the patient's immune system may mount a response against the therapeutic cells. This is less of a concern for ex vivo approaches (where Cas9 is present only transiently during manufacturing) but could be a major issue for in vivo editing approaches.

Manufacturing complexity: Even with CRISPR simplifying certain aspects of cell engineering, the manufacturing process for gene-edited cell therapies remains complex, expensive, and difficult to scale. Allogeneic approaches help but introduce their own challenges around persistence and rejection.

Regulatory uncertainty: Different regulatory agencies have different frameworks for gene-edited cell therapies, and there is no global consensus on what data are required for approval. This creates challenges for companies running international trials and slows the path to market.

Access and equity: Even if allogeneic CAR-T reduces per-dose costs, the overall cost of gene-edited cancer therapy will remain high by global standards. The infrastructure required -- advanced hospitals, specialized oncologists, cell therapy units -- limits access to wealthy countries and well-resourced medical centers. The promise of in vivo approaches to democratize access remains years away from realization.

What Is Coming Next

The next three to five years will be defined by several key developments:

Registrational trials and approvals: Multiple allogeneic CAR-T products, including CTX112 from CRISPR Therapeutics and CB-010 from Caribou Biosciences, are advancing toward registrational trials that could support regulatory approval. The first CRISPR-edited allogeneic CAR-T product could reach the market by 2027 or 2028.

Base editing goes mainstream: The success of BE-CAR7 has validated base editing as a clinical manufacturing technology. Expect more programs to adopt base editing for complex, multi-edited products where the risk of translocations from conventional Cas9 is a concern.

In vivo editing enters the clinic: The first human trials of in vivo CRISPR-based cancer therapy -- likely using LNP-delivered mRNA to reprogram immune cells inside the body -- could begin by 2027. These will be early-phase safety studies, but they will represent a critical milestone.

AI-designed neoantigens: Machine learning models for neoantigen prediction are improving rapidly. Combined with faster manufacturing pipelines, AI-guided personalized CRISPR therapy could reduce turnaround from months to weeks, making it practical for more patients.

Combination strategies: The most effective CRISPR cancer therapies will likely combine multiple modalities -- edited CAR-T or TIL cells, checkpoint modification, tumor microenvironment remodeling, and conventional therapies like radiation or targeted drugs. Clinical trials testing these combinations are already being designed.

Solid tumor breakthroughs: While blood cancers will remain the near-term focus, the accumulated improvements in delivery, multi-antigen targeting, and microenvironment editing are creating conditions for meaningful progress against solid tumors. A CRISPR-edited cell therapy with significant efficacy in a solid tumor indication would be transformative for the field.

Conclusion

CRISPR has not yet cured cancer. No single technology will. Cancer is not one disease but hundreds, each with its own genetic architecture, microenvironment, and evolutionary dynamics. The complexity is humbling.

But CRISPR has done something that previous waves of cancer therapy innovation could not: it has given researchers and clinicians a programmable, precise, and increasingly versatile tool for engineering the immune system to fight cancer on its own terms. The 82 percent remission rate in children with T-ALL treated with base-edited CAR-T cells, the 90 percent response rate in lymphoma patients treated with off-the-shelf allogeneic products, the 100 percent overall response rate in PD-1-knocked-out T cell therapy for B-NHL -- these are not abstract laboratory results. They are clinical outcomes in real patients who were running out of options.

The trajectory is clear. The manufacturing platforms are maturing. The clinical data are strengthening. The delivery technologies are advancing. The economic models for off-the-shelf products are compelling. And the convergence of CRISPR with AI, synthetic biology, and advanced immunology is opening possibilities that were unimaginable when the first CRISPR cancer trial enrolled its first patient in 2016.

The question is no longer whether CRISPR will play a major role in cancer treatment. It already does. The question is how quickly the remaining barriers -- manufacturing scale, delivery precision, solid tumor efficacy, global access -- can be overcome. On the evidence of the past decade, the answer may be: faster than anyone expected.

Sources and Further Reading

Qasim, W. et al. "Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia." New England Journal of Medicine (2023). Published results of the BE-CAR7 trial at Great Ormond Street Hospital.
CRISPR Therapeutics. "CTX112 (Zugo-cel) Clinical Data Presentations." Corporate press releases and conference presentations (2024-2026). Data on allogeneic anti-CD19 CAR-T in LBCL.
Caribou Biosciences. "ANTLER and CaMMouflage Trial Updates." Clinical data presentations at ASH and ASCO (2024-2025). Data on CB-010 and CB-011.
Lu, Y. et al. "CRISPR-Cas9-Mediated PD-1 Disruption Enhances Anti-Tumor Efficacy of CAR-T Cells." Signal Transduction and Targeted Therapy (2023). Clinical results of PD-1 knockout CAR-T in B-NHL.
Rurik, J.G. et al. "CAR T Cells Produced In Vivo to Treat Cardiac Injury." Science (2022). Foundational work on in vivo CAR-T generation using LNPs, extended to oncology applications by UCSF.
Hamilton, J.R. et al. "In Vivo Human T Cell Engineering with Enveloped Delivery Vehicles." Nature Biotechnology (2025). UCSF work on in vivo T cell reprogramming.
Stadtmauer, E.A. et al. "CRISPR-Engineered T Cells in Patients with Refractory Cancer." Science (2020). First U.S. CRISPR cancer trial (University of Pennsylvania), demonstrating safety of multiplex-edited T cells.
Liu, D. "Base Editing: Chemistry, Mechanisms, and Applications." Nature Reviews Methods Primers (2023). Overview of base editing technology by its inventor.
ClinicalTrials.gov. Search: "CRISPR AND cancer." Comprehensive listing of active and completed CRISPR cancer trials.
American Society of Clinical Oncology (ASCO). Annual Meeting abstracts (2024-2025). Multiple presentations on CRISPR-edited cell therapies in oncology.
National Cancer Institute. "CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers." Background resource on CAR-T fundamentals.
Foy, S.P. et al. "Non-Viral Precision T Cell Receptor Replacement for Personalized Cell Therapy." Nature (2023). PACT Pharma neoantigen-directed T cell engineering trial.